Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Male
Humans
Female
Middle Aged
Aged
Gemcitabine
Cisplatin
/ adverse effects
Lung Neoplasms
/ pathology
Retrospective Studies
Antibodies, Monoclonal
/ therapeutic use
Treatment Outcome
Neoplasm Staging
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Neoplasm Recurrence, Local
/ drug therapy
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ pathology
Lung
/ pathology
Chemotherapy
Lung cancer
Necitumumab
Squamous cell carcinoma
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
23
09
2022
accepted:
07
10
2022
pubmed:
5
11
2022
medline:
24
3
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of advanced lung squamous cell carcinoma (LSCC) have been proven. However, the efficacy and safety of N + GC in the second line or later treatment remain unclear. Eleven patients who received N + GC for advanced-stage or recurrent LSCC were enrolled. We retrospectively assessed the patients' clinical characteristics and efficacy and safety of treatment. The median patient age was 73 years (range, 63-77 years). The cohort included nine (81.8%) men and two (18.2%) women. Two (18.2%) patients had postoperative recurrence, and one (9.1%), three (27.3%), one (9.1%), and four (36.4%) patients were diagnosed with stage IIIA, IIIB, IVA, and IVB disease, respectively. Concerning the best overall response, partial response was achieved in five (45.5%) patients, four (36.4%) patients displayed stable disease, and two (18.2%) patients were not evaluable. Median progression-free survival was 6.8 months (range, 1.4-10.3 months). The grade 3 or higher neutropenia, thrombocytopenia, and anemia occurred in six (54.5%), three (27.3%), and two (18.2%) patients, respectively. Additionally, grade 3 skin reaction, rash, lung infection, duodenal ulcer, and febrile neutropenia were observed in one (9.1%) patient each. Two (18.2%) patients required treatment interruption because of adverse events. N + GC displayed good efficacy in the second line or later treatment among patients with LSCC. This study suggested that N + GC is a useful option even after second-line treatment of advanced-stage or recurrent LSCC, although the management of adverse events is essential.
Sections du résumé
BACKGROUND
The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of advanced lung squamous cell carcinoma (LSCC) have been proven. However, the efficacy and safety of N + GC in the second line or later treatment remain unclear.
METHODS
Eleven patients who received N + GC for advanced-stage or recurrent LSCC were enrolled. We retrospectively assessed the patients' clinical characteristics and efficacy and safety of treatment.
RESULTS
The median patient age was 73 years (range, 63-77 years). The cohort included nine (81.8%) men and two (18.2%) women. Two (18.2%) patients had postoperative recurrence, and one (9.1%), three (27.3%), one (9.1%), and four (36.4%) patients were diagnosed with stage IIIA, IIIB, IVA, and IVB disease, respectively. Concerning the best overall response, partial response was achieved in five (45.5%) patients, four (36.4%) patients displayed stable disease, and two (18.2%) patients were not evaluable. Median progression-free survival was 6.8 months (range, 1.4-10.3 months). The grade 3 or higher neutropenia, thrombocytopenia, and anemia occurred in six (54.5%), three (27.3%), and two (18.2%) patients, respectively. Additionally, grade 3 skin reaction, rash, lung infection, duodenal ulcer, and febrile neutropenia were observed in one (9.1%) patient each. Two (18.2%) patients required treatment interruption because of adverse events.
CONCLUSION
N + GC displayed good efficacy in the second line or later treatment among patients with LSCC. This study suggested that N + GC is a useful option even after second-line treatment of advanced-stage or recurrent LSCC, although the management of adverse events is essential.
Identifiants
pubmed: 36331673
doi: 10.1007/s10637-022-01312-9
pii: 10.1007/s10637-022-01312-9
doi:
Substances chimiques
Gemcitabine
0
Cisplatin
Q20Q21Q62J
necitumumab
2BT4C47RUI
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-172Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33
doi: 10.3322/caac.21708
pubmed: 35020204
Perez-Moreno P, Brambilla E, Thomas R et al (2012) Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res 18:2443–2451
doi: 10.1158/1078-0432.CCR-11-2370
pubmed: 22407829
Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med 378:113–125
doi: 10.1056/NEJMoa1713137
pubmed: 29151359
Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med 377:829–838
doi: 10.1056/NEJMoa1704795
pubmed: 28586279
Shaw AT, Ou S-HI, Bang Y-J et al (2014) Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer. N Engl J Med 371:1963–1971
doi: 10.1056/NEJMoa1406766
pubmed: 25264305
pmcid: 4264527
Thatcher N, Hirsch FR, Luft AV et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763–774
doi: 10.1016/S1470-2045(15)00021-2
pubmed: 26045340
Watanabe S, Yoshioka H, Sakai H et al (2019) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. Lung Cancer 129:55–62
doi: 10.1016/j.lungcan.2019.01.005
pubmed: 30797492
Schwartz LH, Litière S, De Vries E et al (2016) RECIST 1.1 - Update and clarification: From the RECIST committee. Eur J Cancer 62:132–137
doi: 10.1016/j.ejca.2016.03.081
pubmed: 27189322
pmcid: 5737828
Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27.US Department of Health and Human Services, National Institutes of Health, National Cancer Institute
Nakao A, Inoue H, Osaki Y et al (2021) Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report. Thorac Cancer 12:2039–2042
doi: 10.1111/1759-7714.13999
pubmed: 34061460
pmcid: 8258358
Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198–211
doi: 10.1016/S1470-2045(20)30641-0
pubmed: 33476593
Reck M, Ciuleanu TE, Cobo M et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.ESMO Open.;6. Epub ahead of print 2021. DOI: https://doi.org/10.1016/j.esmoop.2021.100273
Paz-Ares L, Vicente D, Tafreshi A et al (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 15:1657–1669
doi: 10.1016/j.jtho.2020.06.015
pubmed: 32599071
Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N Engl J Med 381:2020–2031
doi: 10.1056/NEJMoa1910231
pubmed: 31562796
Paz-Ares LG, Ramalingam SS, Ciuleanu TE et al (2022) First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol 17:289–308
doi: 10.1016/j.jtho.2021.09.010
pubmed: 34648948
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 375:1823–1833
doi: 10.1056/NEJMoa1606774
pubmed: 27718847